Tarsus (TARS) Q4 2025 Earnings Call Transcript
The Motley Fool
by newsfeedback@fool.com (Motley Fool Transcribing)February 23, 2026
AI-Generated Deep Dive Summary
Tarsus Pharmaceuticals (TARS) delivered a strong Q4 2025 earnings report, showcasing record net sales and providing its first annual guidance. The company reported full-year net product sales of $451.4 million, with quarterly sales reaching $151.7 million in the fourth quarter. This reflects robust growth driven by the increasing adoption of XDEMVY, Tarsus's lead product for Demodex blepharitis treatment. The company also raised its 2026 net product sales guidance to an impressive $670 million to $700 million, representing a year-over-year increase of over 50% at the midpoint.
Key highlights from the earnings call include Tarsus's strategic focus on expanding XDEMVY's market presence. The company plans to invest in its salesforce by adding 15-20 key account leaders in 2026, aiming to deepen engagement with prescribers. Additionally, Tarsus's direct-to-consumer (DTC) campaign has significantly boosted unaided patient awareness of XDEMVY, rising from 2% to 25% over the course of the campaign. The product's weekly refill rates are steadily increasing, currently in the low- to mid-teens percentage range, with expectations for steady-state levels around 20%.
Tarsus also emphasized its pipeline progress, with two key programs advancing rapidly. TP-04 for ocular rosacea and TP
Verticals
financeinvesting
Originally published on The Motley Fool on 2/23/2026